



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2012

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 6/30/2012 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 6/30/2011 RM'000	CURRENT YEAR TO DATE 6/30/2012 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 6/30/2011 RM'000
Revenue	34,355	35,345	70,412	68,329
Cost of Sales	(17,414)	(19,871)	(38,100)	(39,228)
Gross Profit	16,941	15,474	32,312	29,101
Other operating income	589	67	589	128
Distribution costs	(3,735)	(2,557)	(5,970)	(5,125)
Administration expenses	(3,346)	(3,242)	(7,326)	(6,085)
Other operating expenses	(1,358)	(582)	(1,536)	(1,111)
Profit from operations	9,091	9,160	18,069	16,908
Finance income	53	143	85	279
Finance costs	(107)	(11)	(248)	(21)
Profit before taxation	9,037	9,292	17,906	17,166
Taxation	(2,170)	(2,360)	(4,331)	(4,310)
Profit after tax for the period	6,867	6,932	13,575	12,856
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	6,867	6,932	13,575	12,856
Profit attributable to:				
Shareholders of the Company	6,867	6,932	13,575	12,856
Minority interest	-	-	-	-
	6,867	6,932	13,575	12,856
Total other comprehensive income attributable to:				
Shareholders of the Company	6,867	6,932	13,575	12,856
Minority interest	-	-	-	-
	6,867	6,932	13,575	12,856
Earnings per share (sen)				
Basic (based on weighted average)	4.95	4.99	9.78	9.26
Diluted (based on weighted average)	4.95	4.99	9.78	9.26

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2012

	AS AT 30/6/2012 RM'000	AS AT 31/12/2011 RM'000 Restated (*)	AS AT 1/1/2011 RM'000 Restated (*)
ASSETS			
Property, Plant and Equipment	97,928	95,977	100,249
Investment properties	5,720	5,720	-
Total non-current assets	<u>103,648</u>	<u>101,697</u>	<u>100,249</u>
Inventories	46,797	45,124	34,003
Trade & Other Receivables	38,670	36,911	34,804
Amount Due From Related Company	5,409	769	951
Current tax assets	1,561	2,695	-
Assets classified as held for sale	-	1,740	1,740
Cash & Cash Equivalents	1,846	8,584	24,732
Total current assets	<u>94,283</u>	<u>95,823</u>	<u>96,230</u>
Total Assets	<u><u>197,931</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
EQUITY			
Share Capital	69,739	69,739	69,739
Reserves	-	-	-
Retained earnings	94,762	96,284	89,708
Treasury Shares	(1,578)	(1,578)	(1,578)
Total Equity	<u>162,923</u>	<u>164,445</u>	<u>157,869</u>
LIABILITIES			
Deferred Tax Liability	5,152	5,584	3,821
Borrowings	-	2,082	10,416
Total non-current liabilities	<u>5,152</u>	<u>7,666</u>	<u>14,237</u>
Trade & Other Payables	22,536	14,304	13,509
Amount due to related company	306	2,005	1,324
Provision	766	766	850
Taxation	-	-	356
Borrowings	6,248	8,334	8,334
Total current liabilities	<u>29,856</u>	<u>25,409</u>	<u>24,373</u>
Total Liabilities	<u><u>35,008</u></u>	<u><u>33,075</u></u>	<u><u>38,610</u></u>
Total Equity & Liabilities	<u><u>197,931</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
Net assets per share (RM)	1.17	1.18	1.13

* Upon adoption of MFRS, the Condensed Consolidated Statement of Financial Positions at 31 December 2011 and 1 January 2011 have been restated accordingly.

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 JUNE 2012

	30 June 2012	30 June 2011
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	17,906	17,166
Adjustments for:		
Depreciation of property, plant and equipment	3,347	2,600
Interest income	(85)	(278)
Finance costs	247	-
Gain on disposal of property, plant and equipment	(611)	-
<i>Operating profit before changes in working capital</i>	20,804	19,488
Change in inventories	(1,673)	(5,470)
Change in receivables, deposits and prepayments	(6,516)	(3,049)
Change in payables and accruals	7,373	(213)
<i>Cash generated from operations</i>	19,988	10,756
Finance costs paid	(247)	-
Interest income	85	278
Income tax paid	(4,355)	(4,496)
Net cash generated from operating activities	15,471	6,538
Cash flows from investing activities		
Acquisition of property, plant and equipment	(5,298)	(2,547)
Proceed from disposal of property, plant and equipment	2,352	-
Net cash used in investing activities	(2,946)	(2,547)
Cash flows from financing activities		
Repayment of borrowings	(4,167)	(4,167)
Dividends paid to shareholders of the Company	(15,097)	(15,270)
Net cash used in financing activities	(19,264)	(19,437)
Net decrease in cash and cash equivalents	(6,739)	(15,446)
Cash and cash equivalents at 1 January	8,584	24,732
Cash and cash equivalents as at 30 June	1,845	9,286

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)